---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000148"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:02:10.646213+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger

## Summary
- Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.
- Bonus payable upon closing of the previously announced merger with Decoy Therapeutics.
- Payment subject to Rosenblum's continued employment through the closing date.
- Rosenblum holds dual roles as Acting CEO and Executive VP/CFO.

## SEC filing metadata
- accession: 0001615219-25-000148
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/0001615219-25-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/flks-20251021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000148
- JSON: https://secwatch.observer/filing/0001615219-25-000148.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.